TD Waterhouse Canada Inc. Sells 1,644 Shares of Elevance Health, Inc. $ELV

TD Waterhouse Canada Inc. lessened its holdings in Elevance Health, Inc. (NYSE:ELV) by 19.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,756 shares of the company’s stock after selling 1,644 shares during the period. TD Waterhouse Canada Inc.’s holdings in Elevance Health were worth $2,368,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Artisan Partners Limited Partnership increased its stake in shares of Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after buying an additional 901,626 shares during the period. First Eagle Investment Management LLC increased its stake in shares of Elevance Health by 25.0% in the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after buying an additional 798,457 shares during the period. Brave Warrior Advisors LLC increased its stake in shares of Elevance Health by 65.3% in the third quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock valued at $592,603,000 after buying an additional 724,349 shares during the period. Baupost Group LLC MA increased its stake in shares of Elevance Health by 114.1% in the third quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock valued at $426,195,000 after buying an additional 703,000 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC increased its stake in shares of Elevance Health by 44.2% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock valued at $660,935,000 after buying an additional 627,038 shares during the period. Institutional investors own 89.24% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ELV shares. Barclays lowered their price objective on Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Guggenheim lowered their price objective on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research note on Thursday, January 29th. Sanford C. Bernstein lowered their price objective on Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. UBS Group set a $400.00 price objective on Elevance Health in a research note on Thursday, January 29th. Finally, Wolfe Research set a $425.00 price objective on Elevance Health and gave the company an “outperform” rating in a research note on Thursday, January 8th. Eleven equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $378.30.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q1 results beat and company raised full‑year outlook: Elevance reported Q1 EPS of $12.58 and revenue of $49.49B, topping consensus and saying results reflected improving claims trends; management raised its full‑year adjusted EPS guidance. Elevance Q1 Results & Guidance
• Positive Sentiment: Beat driven by investment income: Net investment income jumped ~29.7%, which materially lifted EPS and helped offset weaker membership and higher medical costs in the quarter. Zacks: ELV Beats on Net Investment Income
• Positive Sentiment: Dividend maintained/increased visibility: Elevance declared a quarterly dividend of $1.72 per share (record June 10), supporting income investors and signaling cash‑flow confidence.
• Neutral Sentiment: Earnings call and detail resources available: Management commentary and the full Q1 call transcript provide detail on claims trends, membership dynamics and cost controls for deeper due diligence. Earnings Call Transcript
• Negative Sentiment: Underlying operational headwinds: Management noted membership declines and elevated medical costs; those trends limit margin upside and create execution risk even as investment income buoyed EPS. Key Metrics Analysis
• Negative Sentiment: Shareholder litigation/investigation announced: Kirby McInerney LLP opened an investigation into potential securities law violations involving the company or senior management — a governance/legal overhang that can pressure the stock. Investor Alert: Investigation
• Negative Sentiment: Guidance vs. Street expectations: Although the company said it raised guidance, its updated FY EPS range remains well below some analyst consensus figures, leaving room for disappointment and analyst revisions.

Elevance Health Stock Performance

NYSE:ELV opened at $326.32 on Thursday. The company has a market capitalization of $71.68 billion, a PE ratio of 12.99, a P/E/G ratio of 1.81 and a beta of 0.49. The company has a 50 day simple moving average of $308.80 and a two-hundred day simple moving average of $331.56. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $432.93.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts anticipate that Elevance Health, Inc. will post 25.75 earnings per share for the current year.

Elevance Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio is currently 27.39%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.